We are live on ! Find out more
JAM

JW Asset Management Portfolio holdings

AUM $244M
1-Year Est. Return 71.51%
This Fund
S&P 500
This Quarter Est. Return
+16.56%
1 Year Est. Return
+71.51%
3 Year Est. Return
+125.61%
5 Year Est. Return
+131.61%
10 Year Est. Return
+2,490.27%
AUM
$157M
AUM Growth
+$55.4M
Cap. Flow
+$39.2M
Cap. Flow %
24.97%
Top 10 Hldgs %
89.61%
Holding
23
New
1
Increased
2
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
CGC
Canopy Growth
CGC
+$39.1M
2
TSLA icon
Tesla
TSLA
+$3.05M
3
ATRS
Antares Pharma, Inc.
ATRS
+$124K

Top Sells

Rank Stock Value
1
CBM
Cambrex Corporation
CBM
+$1.23M
2
CPIX icon
Cumberland Pharmaceuticals
CPIX
+$1.2M
3
ARLZ
Aralez Pharmaceuticals Inc.
ARLZ
+$434K
4
ALIM
Alimera Sciences
ALIM
+$265K

Sector Composition

Rank Sector Weight
1 Healthcare 69.16%
2 Consumer Discretionary 26.86%
3 Technology 3.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGC
1
Canopy Growth
CGC
$377M
$37.8M 24.11%
+129,120
New +$39.1M
EGRX
2
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$36M 22.95%
475,755
– –
AMZN icon
3
Amazon
AMZN
$2.48T
$33.4M 21.27%
392,540
– –
CRON
4
Cronos Group
CRON
$1.06B
$7.25M 4.62%
1,111,444
– –
TSLA icon
5
Tesla
TSLA
$1.21T
$5.14M 3.28%
225,000
+150,000
+200% +$3.05M
ATRS
6
DELISTED
Antares Pharma, Inc.
ATRS
$4.7M 2.99%
1,820,524
+50,000
+3% +$124K
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.48M 2.86%
270,775
– –
MSFT icon
8
Microsoft
MSFT
$2.92T
$4.09M 2.61%
41,500
– –
PETQ
9
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
$4M 2.55%
148,855
– –
JNP
10
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
$3.71M 2.37%
426,903
– –
BSTC
11
DELISTED
BioSpecifics Technologies Corp.
BSTC
$3.3M 2.11%
73,649
– –
BABA icon
12
Alibaba
BABA
$276B
$3.29M 2.1%
17,750
– –
LGND icon
13
Ligand Pharmaceuticals
LGND
$5.94B
$2.78M 1.77%
21,482
– –
AVDL
14
DELISTED
Avadel Pharmaceuticals
AVDL
$2.72M 1.74%
444,439
– –
MU icon
15
Micron Technology
MU
$927B
$2.15M 1.37%
41,000
– –
NVLN
16
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$1.16M 0.74%
315,979
– –
ALIM
17
DELISTED
Alimera Sciences
ALIM
$404K 0.26%
27,553
-18,847
-41% -$265K
BBBY
18
Bed Bath & Beyond
BBBY
$503M
$337K 0.21%
13,310
– –
SNOA icon
19
Sonoma Pharmaceuticals
SNOA
$5.46M
$102K 0.07%
228
– –
TLGT
20
DELISTED
Teligent, Inc
TLGT
$48K 0.03%
1,382
– –
CPIX icon
21
Cumberland Pharmaceuticals
CPIX
$102M
– –
-178,942
Closed -$1.2M
CBM
22
DELISTED
Cambrex Corporation
CBM
– –
-23,519
Closed -$1.23M
ARLZ
23
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
– –
-289,664
Closed -$434K

Similar funds

SC
Schulhoff & Co Cincinnati, Ohio $243M AUM 17.47% 1-Year Est. Return
HCM
Hutner Capital Management Manchester, Vermont $243M AUM 10.01% 1-Year Est. Return
SC
Solstein Capital Menlo Park, California $244M AUM 29.05% 1-Year Est. Return
HBS
Howard Bailey Securities Fort Wayne, Indiana $243M AUM 13.36% 1-Year Est. Return
GIM
GE Investment Management Norwalk, Connecticut $244M AUM 41.62% 1-Year Est. Return
IFO
Independent Family Office Albany, New York $243M AUM 21.81% 1-Year Est. Return
VG
Visualize Group New York $243M AUM 6.21% 1-Year Est. Return
CP
Creekside Partners Petaluma, California $243M AUM 20.23% 1-Year Est. Return

JW Asset Management's Q2 2018 Portfolio in Review

As of Q2 2018, JW Asset Management held 23 positions worth $157M, up 55% from $101M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

JW Asset Management deployed $39.2M of net new capital in Q2 2018, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Canopy Growth: 129,120 shares worth $37.8M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 61% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Alimera Sciences, an estimated $265K trimmed.

  • JW Asset Management's largest Q2 2018 buy was Canopy Growth: 129,120 shares worth $37.8M.
  • JW Asset Management added most to Tesla in Q2 2018, an estimated $3.05M increase.
  • JW Asset Management's biggest Q2 2018 reduction was Alimera Sciences, cutting an estimated $265K.
  • JW Asset Management fully exited Cambrex Corporation in Q2 2018, selling an estimated $1.23M.
  • JW Asset Management's ten largest holdings make up 90% of its $157M portfolio in Q2 2018.
  • JW Asset Management opened 1 new position and closed 3 in Q2 2018.
  • JW Asset Management's portfolio value rose 55% quarter-over-quarter to $157M.

Based on JW Asset Management's 13F filing for Q2 2018, filed 10 Aug 2018.